rapt
therapeutics
appoints
lisa
butterfield
lawrence
fong
scientific
advisory
board
south
san
francisco
globe
newswire
rapt
therapeutics
nasdaq
rapt
biopharmaceutical
company
focused
discovering
developing
commercializing
oral
small
molecule
therapies
patients
significant
unmet
needs
oncology
inflammatory
diseases
today
announced
addition
preeminent
oncology
thought
leaders
lisa
butterfield
lawrence
fong
scientific
advisory
board
exciting
time
field
deeper
knowledge
biological
functions
elucidating
new
ways
treat
disease
effectively
commented
butterfield
rapt
comprehensive
approach
clinical
development
employing
biomarkers
identify
patients
likely
respond
therapy
offers
hope
even
devastating
butterfield
vice
president
research
development
parker
institute
cancer
immunotherapy
adjunct
professor
microbiology
immunology
university
california
san
francisco
research
focuses
development
advanced
cellular
therapies
cancer
vaccines
investigates
immunotherapy
hepatocellular
cancer
melanoma
involving
peptides
dendritic
cells
adenoviruses
well
effector
responses
tumor
antigens
previously
served
professor
medicine
surgery
immunology
clinical
translational
science
university
pittsburgh
director
hillman
cancer
center
immunologic
monitoring
cellular
products
laboratory
member
sitc
executive
committee
years
serving
president
decade
butterfield
led
immunology
reference
lab
nci
cooperative
group
butterfield
received
biology
ucla
completed
postdoctoral
fellowship
cellular
immunology
cancer
gene
therapy
ucla
published
manuscripts
reviews
book
chapters
rapt
uniquely
tapped
crossroad
within
immunology
impacts
allergy
cancer
mechanisms
said
fong
look
forward
contributing
research
development
progress
advancing
pipeline
oral
small
molecules
offer
promise
patients
around
lawrence
fong
efim
guzik
distinguished
professor
division
hematology
oncology
university
california
san
francisco
ucsf
focuses
developing
immunotherapies
different
cancers
including
prostate
kidney
bladder
melanoma
gi
cancers
fong
also
leads
translational
immunotherapy
laboratory
involved
preclinical
clinical
studies
many
immunotherapies
directs
cancer
immunotherapy
program
ucsf
helen
diller
family
comprehensive
cancer
center
fong
obtained
stanford
university
completed
internal
medicine
training
university
washington
served
program
committees
editorial
boards
american
society
clinical
oncology
asco
american
association
cancer
research
aacr
parker
institute
cancer
immunotherapy
ucsf
site
primary
investigator
cancer
immunotherapy
trials
network
citn
delighted
welcome
two
immunotherapy
leaders
scientific
advisory
board
said
dirk
brockstedt
chief
scientific
officer
rapt
therapeutics
lisa
brings
incredible
expertise
development
cellular
therapies
well
insight
serving
leadership
role
two
organizations
dedicated
developing
effective
therapies
cancer
patients
larry
experience
conducting
wide
range
clinical
preclinical
trials
across
varied
cancers
provide
integral
guidance
advance
clinical
development
complete
studies
pipeline
rapt
therapeutics
rapt
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovering
developing
commercializing
oral
small
molecule
therapies
patients
significant
unmet
needs
oncology
inflammatory
diseases
utilizing
proprietary
discovery
development
engine
company
developing
highly
selective
small
molecules
designed
modulate
critical
immune
drivers
underlying
diseases
rapt
discovered
advanced
two
unique
drug
candidates
targeting
motif
chemokine
receptor
treatment
cancer
inflammation
respectively
company
also
pursuing
range
targets
including
hematopoietic
progenitor
kinase
general
control
nonderepressible
discovery
stage
development
statements
press
release
contains
statements
statements
relate
future
events
involve
known
unknown
risks
uncertainties
factors
may
cause
actual
results
performance
achievements
materially
different
future
performances
achievements
expressed
implied
statements
statements
based
current
information
assumptions
expectations
inherently
subject
change
involve
number
risks
uncertainties
statements
include
limited
statements
clinical
development
progress
timing
results
clinical
trials
detailed
information
regarding
risk
factors
may
cause
actual
results
differ
materially
results
expressed
implied
statements
press
release
may
found
rapt
form
filed
securities
exchange
commission
august
subsequent
filings
made
rapt
securities
exchange
commission
statements
speak
date
hereof
rapt
disclaims
obligation
update
statements
rapt
media
contact
angela
bitting
media
rapt
investor
contact
sylvia
wheeler
swheeler
